This content is from: Sponsored Content
Drug companies swallow Japan’s bitter pill
Swiss pharmaceutical manufacturer Novartis is the latest company to feel the wrath of the Japanese authorities over transfer pricing. The Japanese government has fined Novartis' Japanese subsidiary, Ciba-Geigy Japan, ¥3.3 billion ($28 million) for underreporting its income by ¥8 billion between 1990 and 1994.
Get Free Access to read more …
Read the full article and get instant full access for free
Get Free Access- Full free access for a week in a few clicks
- No commitments, no payment details
- Feauturing transfer pricing analysis
Are you ITR or TP week subscriber? Please log in.